You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Romidepsin

Showing 1 - 25 of 98
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Romidepsin
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

HIV-1-infection, Subtype b Trial (Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2)

Recruiting
  • HIV-1-infection, Subtype b
  • Decitabine cycle 1
  • +7 more
  • Bruxelles, Belgium
  • +2 more
Jan 30, 2023

Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)

Recruiting
  • Lymphoma, T-Cell
  • Charlottesville, Virginia
    University of Virginia
Mar 16, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Pembrolizumab
  • Romidepsin
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Multiple Myeloma, Non-Hodgkin's Lymphoma Trial in United States (Romidepsin, Lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Hartford, Connecticut
  • +6 more
Jan 3, 2023

PTCL Trial in Long Beach, New Haven, Charlottesville (Azacytidine, Romidepsin, Belinostat)

Recruiting
  • PTCL
  • Long Beach, California
  • +2 more
Mar 1, 2022

Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia Trial in Columbus (Romidepsin, Busulfan,

Recruiting
  • Cutaneous T-cell Lymphoma
  • +4 more
  • Romidepsin
  • +4 more
  • Columbus, Ohio
    The Ohio State University Cancer Center
Apr 18, 2022

Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
  • +1 more
Jul 26, 2022

Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)

Active, not recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Romidepsin
  • +2 more
  • Stanford, California
  • +10 more
Feb 2, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 6, 2022

HIV Trial in United States (Romidepsin, Placebo for Romidepsin)

Completed
Has Results
  • HIV Infections
  • Romidepsin
  • Placebo for Romidepsin
  • Birmingham, Alabama
  • +9 more
Oct 28, 2021

Triple-Negative Breast Cancer, Breast Cancer Trial in United States (Romidepsin, Cisplatin, Nivolumab)

Active, not recruiting
  • Triple-Negative Breast Cancer
  • Breast Cancer
  • Romidepsin
  • +2 more
  • Fairway, Kansas
  • +6 more
Nov 19, 2021

Colorectal Cancer Trial in Baltimore (Oral CC-486, Romidepsin, MK-3475)

Completed
  • Colorectal Cancer
  • Oral CC-486
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 21, 2022

Lung Cancer, Metastatic Cancer Trial in Dallas (Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2),

Completed
Has Results
  • Lung Cancer
  • Metastatic Cancer
  • Erlotinib plus Romidepsin (8 mg/m^2)
  • +3 more
  • Dallas, Texas
    Simmons Comprehensive Cancer Center at University of Texas South
Jan 18, 2021

Hiv Trial in Denmark, United Kingdom (Romidepsin, 3BNC117, Antiretrovirals)

Active, not recruiting
  • Hiv
  • Romidepsin
  • +2 more
  • Aalborg, Denmark
  • +6 more
Sep 3, 2021

Human Immunodeficiency Virus (HIV) Trial in New York, Aarhus, Cologne (3BNC117, Romidepsin)

Completed
  • Human Immunodeficiency Virus (HIV)
  • New York, New York
  • +2 more
Feb 3, 2021

Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Trial in Germany (Romidepsin, Azacitidine,

Recruiting
  • Pancreas Cancer
  • +2 more
  • Romidepsin
  • +5 more
  • Essen, Germany
  • +8 more
May 17, 2022

Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma Trial in New York (Romidepsin, Oral 5-Azacitidine)

Terminated
  • Lymphoid Malignancies
  • +3 more
  • Romidepsin
  • Oral 5-Azacitidine
  • New York, New York
    Columbia University Medical Center
Jan 5, 2021

Lymphoma, T-Cell, Peripheral Trial in United States (Romidepsin, Ixazomib)

Active, not recruiting
  • Lymphoma, T-Cell, Peripheral
  • Chicago, Illinois
  • +6 more
Jan 15, 2021

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease Trial in Chicago, Saint Louis (Romidepsin,

Completed
  • Lymphoma, T-Cell, Cutaneous
  • +3 more
  • Romidepsin
  • +4 more
  • Chicago, Illinois
  • +1 more
Nov 16, 2020

Peripheral T-cell Lymphoma Trial in Worldwide (Romidepsin + CHOP, CHOP)

Completed
  • Peripheral T-cell Lymphoma
  • Antwerpen, Belgium
  • +130 more
Jan 9, 2023

Lymphoma, T-Cell Trial (Copanlisib, Romidepsin)

Withdrawn
  • Lymphoma, T-Cell
  • (no location specified)
Aug 11, 2020

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma Trial in New Haven (lenalidomide (Revlimid) and romidepsin

Terminated
  • Hodgkin's Lymphoma
  • +2 more
  • lenalidomide (Revlimid) and romidepsin (Istodax)
  • New Haven, Connecticut
    Yale Cancer Center
Mar 2, 2020